Gadolinium Exposure From MRI Not Linked to Parkinsonism

This article originally appeared here.
Share this content:
Gadolinium Exposure From MRI Not Linked to Parkinsonism
Gadolinium Exposure From MRI Not Linked to Parkinsonism

WEDNESDAY, July 6, 2016 (HealthDay News) -- Gadolinium exposure seems not to be associated with parkinsonism, according to a research letter published online July 5 in the Journal of the American Medical Association.

Blayne Welk, M.D., from Western University in London, Canada, and colleagues conducted a population-based study to examine the correlation between gadolinium exposure and parkinsonism. Patients older than 66 years who underwent an initial magnetic resonance imaging (MRI) exam between April 2003 and March 2013 were identified. The primary outcome, a new diagnosis of parkinsonism based on a validated definition, was evaluated in patients who were exposed to gadolinium-enhanced MRIs versus patients who received non-gadolinium-enhanced MRIs. Data were included for 246,557 patients undergoing at least one MRI, of whom 40.5 percent received at least one dose of gadolinium.

The researchers found that the most common initial non-gadolinium-enhanced MRI was of an extremity and that the most common gadolinium-enhanced MRI was of the abdomen (76 and 39.2 percent, respectively). Incident parkinsonism developed in 1.16 and 1.17 percent of unexposed patients and those exposed to gadolinium, respectively. In adjusted analysis, among patients with cumulative gadolinium exposure, there was no significantly increased risk of parkinsonism compared with those exposed to non-gadolinium-enhanced MRIs (hazard ratio, 1.04; 95 percent confidence interval, 0.98 to 1.09).

"This result does not support the hypothesis that gadolinium deposits in the globus pallidi lead to neuronal damage manifesting as parkinsonism," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease


More in Home

ASTRO: No Survival Benefit for Adding EBT to Brachytherapy

ASTRO: No Survival Benefit for Adding EBT to ...

Addition of external beam therapy doesn't improve five-year progression-free survival in prostate cancer

ASTRO: Fewer Side Effects With IMRT in Cervical, Endometrial CA

ASTRO: Fewer Side Effects With IMRT in Cervical, ...

Patients in conventional radiotherapy arm had more high-level adverse events than those in IMRT arm

Many Doctors Reluctant to Reveal Mental Health Issues

Many Doctors Reluctant to Reveal Mental Health Issues

Perceived stigma, fear of career repercussions hinder treatment, study suggests

is free, fast, and customized just for you!

Already a member?

Sign In Now »